ArticleFrontiers in oncology2025
Proposed observational study protocol for early differentiation of cytokine release syndrome and sepsis in CAR-T recipients with haematological malignancies using the IL-6/PCT ratio: the DRACARYS study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionised treatment for haematological malignancies, demonstrating remarkable efficacy in B-cell leukaemias, lymphomas, and multiple myeloma. However, severe toxicities-particularly Cytokine Release Syndrome (CRS) and sepsis-present significant clinical challenges. Both conditions share overlapping features, including fever, hypotension, and multi-organ dysfunction, making timely and accurate differentiation essential. CRS is driven by excessive cytokine release, predominantly IL-6, and is treated with IL-6 receptor blockade (tocilizumab) and corticosteroids. Sepsis, by contrast, results from a dysregulated immune response to infection and requires antibiotics, as well as supportive care. Due to diagnostic uncertainty, clinicians often treat both conditions empirically. This can lead to inappropriate therapies-immunosuppressives may worsen sepsis, while antibiotics in CRS contribute to antimicrobial resistance and unnecessary healthcare burden. Existing biomarkers, such as IFN-γ and IL-1β, have shown potential but are limited by cost, availability, and the lack of rapid bedside implementation. There is a pressing need for a clinically accessible and reliable biomarker to distinguish CRS from sepsis in CAR-T patients. We hypothesise that the IL-6/procalcitonin (PCT) ratio will improve diagnostic accuracy. IL-6 is elevated in both conditions, while PCT is more specific to bacterial infection. However, PCT alone may be unreliable in immunocompromised patients, such as those receiving CAR-T therapy. The IL-6/PCT ratio is expected to reduce inter-individual variability and address limitations inherent to each marker when used alone. In this multi-centre, observational, prospective study, we will evaluate the IL-6/PCT ratio in febrile CAR-T patients. The primary analysis will focus on relapsed/refractory B-cell lymphomas, with a prespecified expansion/validation across other CAR-T indications. Clinical adjudication will serve as the standard of reference. We will assess diagnostic performance using Receiver Operating Characteristic (ROC) analysis to determine sensitivity, specificity, and optimal cutoffs. This study, titled
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.